SCHEMBL9922277

SCHEMBL9922277

CS(=O)(=O)c1ccc2c(c1)C(=O)N(c1ccc(NC(=O)NS(=O)(=O)c3ccc(Cl)s3)cc1F)C(=O)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 2/20 0.43
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KCNA1 Q09470 6/20 0.36
KCNAB1 Q14722 6/20 0.36
GRM1 Q13255 1/20 0.36
F10 P00742 1/20 0.36
FBP1 P09467 1/20 0.35
MAPT P10636 1/20 0.34
APP P05067 3/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
TP53 P04637 1/20 0.33
GAA P10253 1/20 0.33
CASP6 P55212 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922091 0.93 GRM1 (0.42) P2RY12MEN1KMT2AKCNA1KCNAB1
SCHEMBL9922804 0.92 P2RY12 (0.42) P2RY12MEN1KMT2AKCNA1KCNAB1
SCHEMBL9922801 0.91 P2RY12 (0.44) P2RY12MEN1KMT2AKCNA1KCNAB1
SCHEMBL9922802 0.90 P2RY12 (0.43) P2RY12MEN1KMT2AKCNA1KCNAB1
SCHEMBL9922799 0.89 P2RY12 (0.42) P2RY12MEN1KMT2AKCNA1KCNAB1
SCHEMBL9922276 0.88 KMT2A (0.44) P2RY12MEN1KMT2AKCNA1KCNAB1
SCHEMBL9922274 0.88 P2RY12 (0.43) P2RY12MEN1KMT2AKCNA1KCNAB1
SCHEMBL9923094 0.88 CASP6 (0.46) P2RY12MEN1KMT2AGRM1F10
SCHEMBL9922794 0.88 P2RY12 (0.44) P2RY12MEN1KMT2AKCNA1KCNAB1
SCHEMBL9922273 0.88 APP (0.43) P2RY12KCNA1KCNAB1GRM1FBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524721-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2013-09-03 US disclosed
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-7622474-B2 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-24 US disclosed
US-20080194597-A1 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2008-08-14 US disclosed
US-7358257-B2 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents PORTOLA PHARMACEUTICALS, INC. (US) 2008-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 19/4885MEN1 4498/4885KMT2A 3009/4885
US-20080194597-A1 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PIGS, GP6, ASGR1 P2RY12 89/4885MEN1 4750/4885KMT2A 3608/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885MEN1 4499/4885KMT2A 3023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.